Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-954 in healthy adults
NCT03870555Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of felcisetrag in Postoperative gastrointestinal dysfunction (POGD), enteral feeding intolerance (EFI) and gastroparesis (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Reporting One or More Treatment-emergent Adverse Events, Number of Participants With Clinically Significant Change From Baseline in Vital Signs and 10 more. Started Mar 2019; status: completed.
02
Drugs
felcisetrag
03
Conditions
Postoperative gastrointestinal dysfunction (POGD)enteral feeding intolerance (EFI)gastroparesis
Beyond the preview
Go deeper on NCT03870555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870555.